In Vivo BCMA/GPRC5D Tandem Dual CAR-T Therapy for Relapsed/Refractory Plasma Cell Neoplasms

StatusRecruiting
PhaseEarly Phase 1
SponsorLiping Dou
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 4 more changesShow less
    • Study sites: 0 to 1
    • Interventions: In vivo BCMA/GPRC5D Tandem Dual CAR-T cell (Drug) to In vivo BCMA/GPRC5D Tandem Dual CAR-T cell (Drug)
    • Eligibility criteria expanded, about 25 words
    • Secondary endpoints: details revised at 2 of 9 entries
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Liping Dou
9 trials monitored
See 1 trial at risk
This study aims to assess the safety profile of in vivo BCMA/GPRC5D-targeted CAR-T cell immunotherapy in patients with relapsed or refractory plasma cell neoplasms.
Trial Details
NCT Number NCT07586709
Lead Sponsor Liping Dou
Conditions
(from sponsor)		 Plasma Cell Neoplasms
Related terms Neoplasms, Plasma Cell
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov